Fulltext

The cost reduction in hospitalization associated with paliperidone palmitate in the People's Republic of China, Korea, and Malaysia

Chiou CF 1 , Wang BC 2 , Caldwell R 3 , Furnback W 2 , Lee JS 4 , Kothandaraman N 5 Show all authors , Lee S 6 , Wang J 7 , Zhang F 8

Affiliations 

  • 1 Regional Market Access, Janssen Asia-Pacific, Singapore
  • 2 Elysia Group, LLC, Taipei, Taiwan
  • 3 Department of Economics, University of Michigan, Ann Arbor, MI, USA
  • 4 Department of Psychiatry, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea
  • 5 Government Affairs, Johnson & Johnson Sdn Bhd, Selangor, Malaysia
  • 6 Market Access, Janssen Korea Ltd, Seoul, Korea
  • 7 Strategy and Development, Xian Janssen Pharmaceutical Co, Ltd, Beijing, People's Republic of China
  • 8 Medical Affairs, Xian Janssen Pharmaceutical Co, Ltd, Beijing, People's Republic of China
Neuropsychiatr Dis Treat, 2015;11:1989-94.
PMID: 26346330 DOI: 10.2147/NDT.S86722

Abstract

Schizophrenia results in substantial health care utilization costs. Much of these costs can be attributed to health care use resulting from nonadherence to treatment, relapse, and hospitalization.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications